Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparX: Denosumab plus neoadjuvant chemotherapy and nab-paclitaxel schedules in primary breast cancer
2015-001755-72Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of denosumab in breast cancer (4 arms), sponsored by GBG Forschungs. Primary endpoints: Pathological complete response (pCR) and Interaction of denosumab treatment with RANK expression. Started Sep 2016; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-001755-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001755-72.